1. Scrip

Gritstone Jumps Into COVID-19 Vaccine Race, Eyeing Mutant Strains

Potentially Resistant Strains Raise Worries

 
• By Alaric DeArment

The company is developing a vaccine with both adenoviral and mRNA technology that could potentially overcome resistance mutations on the SARS-CoV-2 spike protein.

COVID-19 vaccine
Gritstone is developing a vaccine designed to potentially overcome mutant strains of coronavirus. • Source: Shutterstock

As efforts are underway to vaccinate people against SARS-CoV-2, concerns have arisen about new strains of the virus that display greater infectivity than the original and possibly even resistance to existing vaccines. With that in mind, Gritstone Oncology, Inc. is looking to develop a vaccine that it hopes may protect against the mutant strains.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.